Enterprise Value

0.00

Cash

10.51B

Avg Qtr Burn

N/A

Short % of Float

0.00%

Insider Ownership

0.00%

Institutional Own.

0.38%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Polivy (CD79b) w/ R-CHP Details
Cancer, Diffuse large B cell lymphoma

Approved

Quarterly sales

Columvi® (glofitamab-gxbm) Details
Diffuse large B cell lymphoma, Cancer

Approved

Quarterly sales

Vabysmo® (faricimab) Details
Retinal vein occlusion

Approved

Quarterly sales

Alecensa® (alectinib) Details
Non-small cell lung carcinoma

Approved

Quarterly sales

Xolair® (omalizumab) Details
Allergic Reactions (type I), Allergy

Approved

Quarterly sales

Evrysdi (risdiplam) Details
Rare diseases, Spinal muscular atrophy

Approved

Quarterly sales

Mosunetuzumab (Lunsumio) Details
Cancer, Blood cancer, Follicular lymphoma

Approved

Quarterly sales

Tecentriq w/ ENHANZE® Details
Cancer, Solid tumor/s

PDUFA

Approval decision

Fenebrutinib Details
Multiple sclerosis, Autoimmune disease

Phase 3

Data readout

Tecentriq SC (subcutaneous) Details
Cancer, Non-small cell lung carcinoma

Phase 3

Data readout

Tecentriq+/- Tiragolumab Details
Cancer, Non-small cell lung carcinoma

Phase 3

Data readout

Tecentriq® (atezolizumab) +Chemo Details
Solid tumor/s, Cancer, Triple-negative breast cancer

Phase 3

Data readout

Columvi® + GemOx Details
Diffuse large B cell lymphoma, Cancer, Blood cancer

Phase 3

Data readout

Lunsumio + Polivy Details
Cancer, Blood cancer, Diffuse large B cell lymphoma

Phase 3

Data readout

Gantenerumab Details
Alzheimer's disease

Phase 3

Update

Crovalimab Details
Paroxysmal nocturnal hemoglobinuria

Phase 3

Update

Inavolisib + palbociclib & fulvestrant Details
Cancer, ER+/HER2- breast cancer, Breast cancer

Phase 3

Update

Phase 3

Update

Phase 3

Update

Tecentriq® (atezolizumab) +Avastin® Details
Solid tumor/s, Cancer, Hepatocellular carcinoma

Phase 3

Update

Anti-IL-6 monoclonal antibody Details
Eye disease , Macular edema

Phase 1

Update